avapro and Elevated Cholesterol
avapro has been researched along with Elevated Cholesterol in 9 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"A once-daily combination product of irbesartan and atorvastatin provided an effective, safe, and more compliable treatment for patients with coexisting hypertension and hyperlipidemia." | 9.22 | Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study. ( Chae, SC; Cho, DG; Chung, MH; Ha, JW; Han, GR; Hyon, MS; Jo, SH; Kim, CH; Kim, DW; Kim, KS; Kim, SH; Kim, YD; Lee, HL; Lee, NH; Lee, SC; Lee, SY; Oh, BH; Park, CG; Ryu, GH; Seung, KB; Yoon, MH, 2016) |
"Cardiac hypertrophy is not only an adaptational state before heart failure but also is an independent risk factor for ischemia, arrhythmia, and sudden death." | 5.36 | The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats. ( Hu, D; Li, Y; Liu, N; Ren, L; Sheng, Z; Tang, R, 2010) |
"A once-daily combination product of irbesartan and atorvastatin provided an effective, safe, and more compliable treatment for patients with coexisting hypertension and hyperlipidemia." | 5.22 | Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study. ( Chae, SC; Cho, DG; Chung, MH; Ha, JW; Han, GR; Hyon, MS; Jo, SH; Kim, CH; Kim, DW; Kim, KS; Kim, SH; Kim, YD; Lee, HL; Lee, NH; Lee, SC; Lee, SY; Oh, BH; Park, CG; Ryu, GH; Seung, KB; Yoon, MH, 2016) |
"Hypercholesterolemia is an important risk factor for atherosclerotic vascular disease including stroke." | 2.73 | Effects of angiotensin II type 1-receptor blockade on retinal endothelial function. ( Harazny, J; Michelson, G; Ott, C; Schlaich, MP; Schmidt, BM; Schmieder, RE, 2008) |
"Atherosclerosis is a chronic inflammatory disease in which the renin-angiotensin-aldosterone system plays an important role." | 1.36 | Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice. ( Chen, Y; Cheng, X; Ding, YJ; Liao, MY; Liao, YH; Tang, TT; Xie, JJ; Yao, R; Yu, X, 2010) |
"Cardiac hypertrophy is not only an adaptational state before heart failure but also is an independent risk factor for ischemia, arrhythmia, and sudden death." | 1.36 | The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats. ( Hu, D; Li, Y; Liu, N; Ren, L; Sheng, Z; Tang, R, 2010) |
Research
Studies (9)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Kim, SH | 1 |
Jo, SH | 1 |
Lee, SC | 1 |
Lee, SY | 1 |
Yoon, MH | 1 |
Lee, HL | 1 |
Lee, NH | 2 |
Ha, JW | 1 |
Kim, DW | 1 |
Han, GR | 1 |
Hyon, MS | 1 |
Cho, DG | 1 |
Park, CG | 1 |
Kim, YD | 1 |
Ryu, GH | 1 |
Kim, CH | 1 |
Kim, KS | 1 |
Chung, MH | 1 |
Chae, SC | 1 |
Seung, KB | 1 |
Oh, BH | 1 |
Yao, R | 1 |
Cheng, X | 1 |
Chen, Y | 1 |
Xie, JJ | 1 |
Yu, X | 1 |
Liao, MY | 1 |
Ding, YJ | 1 |
Tang, TT | 1 |
Liao, YH | 1 |
Ren, L | 1 |
Li, Y | 2 |
Tang, R | 1 |
Hu, D | 1 |
Sheng, Z | 1 |
Liu, N | 1 |
Alexandru, N | 2 |
Popov, D | 2 |
Dragan, E | 2 |
Andrei, E | 2 |
Georgescu, A | 2 |
Titorencu, I | 1 |
Tarziu, C | 1 |
Ghiorghe, S | 1 |
Badila, E | 1 |
Bartos, D | 1 |
Chade, AR | 1 |
Rodriguez-Porcel, M | 1 |
Rippentrop, SJ | 1 |
Lerman, A | 1 |
Lerman, LO | 1 |
Morawietz, H | 1 |
Erbs, S | 1 |
Holtz, J | 1 |
Schubert, A | 1 |
Krekler, M | 1 |
Goettsch, W | 1 |
Kuss, O | 1 |
Adams, V | 1 |
Lenk, K | 1 |
Mohr, FW | 1 |
Schuler, G | 1 |
Hambrecht, R | 1 |
Ott, C | 1 |
Schlaich, MP | 1 |
Harazny, J | 1 |
Schmidt, BM | 1 |
Michelson, G | 1 |
Schmieder, RE | 1 |
Sanz, M | 1 |
Ganado, P | 1 |
Tejerina, T | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia[NCT01442987] | Phase 3 | 230 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
3 trials available for avapro and Elevated Cholesterol
Article | Year |
---|---|
Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study.
Topics: Aged; Antihypertensive Agents; Atorvastatin; Biphenyl Compounds; Blood Pressure; Cholesterol; Double | 2016 |
Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Blood Pressure; Choles | 2006 |
Effects of angiotensin II type 1-receptor blockade on retinal endothelial function.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Double-Blind Method; Endothelium | 2008 |
Other Studies
6 other studies available for avapro and Elevated Cholesterol
Article | Year |
---|---|
Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Bipheny | 2010 |
The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Cardiomegaly; Cholesterol, Dietary; Hypercholesterolemi | 2010 |
Platelet activation in hypertension associated with hypercholesterolemia: effects of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Biphenyl Co | 2011 |
Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biphenyl Compounds; Blood Pressur | 2012 |
Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Hemodynamics; Hypercho | 2003 |
Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Biphenyl Compounds; Chole | 2002 |